Please login to the form below

Not currently logged in
Email:
Password:

Celltrion

This page shows the latest Celltrion news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar and Xeljanz

Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar and Xeljanz

GlobalData predicts Trazimera can earn $9m in its first year, far behind the forecast 12 month totals for Celltrion and Mundipharma’s Herzuma ($59m), Amgen’s Kanjinti ($33m), and Samsung Bioepsis

Latest news

More from news
Approximately 13 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    This has provided an opportunity for companies specialising in development of biosimilars to win deals from big companies, such as the $160m agreement between Teva and Celltrion in the US and

  • Deal Watch October 2016 Deal Watch October 2016

    For example in Europe both Pfizer (Hospira) in 2009 and Mundipharma in 2014 have rights to Celltrion's infliximab. ... 175. Celltrion (SK). Teva (IS). Co-commercialisation. Biosimilar rituximab and trastuzumab in phase III in North America.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    This first infliximab biosimilar was developed and manufactured by Celltrion and is marketed by various partners, notably Hospira under the brand name Inflectra and Mundipharma as Remsima.

  • Pharma deals in February 2015 Pharma deals in February 2015

    Assets that Hospira acquired with Celltrion are essentially replicas of existing Pfizer programmes eg Herceptin and Rituxan and these will probably be divested.

  • Current development and marketing of biosimilar monoclonal antibodies in Latin America Current development and marketing of biosimilar monoclonal antibodies in Latin America

    Celltrion. South Korea. CT-P10. Clinical. FL: Phase III started in Dec 2011. ... 7). OliMed. Trastuzumab. Celltrion. South Korea. CT-P06. Clinical. BC: Ph III completed in Dec 2011.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics